My thought is to get the costs down so that all people have access to this in a secure manner that also reduces expenses.
The World Health Organization recently put out its first advice on using glucagon-like peptide-1 treatments for obesity. It gives a conditional nod to the drug class for ongoing use in adults who are not pregnant, together with a healthy diet, exercise and medical advice. Demand for these hunger-reducing drugs has risen sharply since weight-loss approvals began a few years ago. Spending on them in the US has grown more than fivefold in five years. A month's supply there is expensive, and the WHO expects most of the billions of people with obesity worldwide will not be able to obtain the therapies by 2030. The guidance pushes for wider access via measures like tiered pricing and stronger controls on counterfeit versions.